Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Cancer vaccines and immune checkpoint inhibitors (ICIs) function at different stages of the
cancer immune cycle due to their distinct mechanisms of action. Therapeutic cancer …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …

Pancreatic ductal adenocarcinoma is associated with a poor prognosis and there are few
treatment options. The development of immunotherapy in pancreatic ductal adenocarcinoma …

Dendritic cells (DCs), a class of professional antigen-presenting cells, are considered key
factors in the initiation and maintenance of anti-tumor immunity due to their powerful ability …

Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro,
with or without genetic modification, is a rapidly growing area of drug development, even …

The lack of response to therapy in pancreatic ductal adenocarcinoma (PDAC) patients has
contributed to PDAC having one of the lowest survival rates of all cancer types. The poor …

Increasingly, patients with gastrointestinal tumors can benefit from immunotherapy, but not
patients with pancreatic cancer. While this lack of benefit has been attributed to lower T-cell …

The mutation of the crucial genes such as tumor suppressors or oncogenes plays an
important role in the initiation and development of tumors. The non-synonymous mutations …